Almond Jeffrey, Medaglini Donata
University of Oxford, The Sir William Dunn School of Pathology, South Parks Road, Oxford OX1 3RE, UK.
University of Siena, Department of Medical Biotechnologies, 53100 Siena, Italy.
Vaccine. 2017 Jan 20;35 Suppl 1:A24-A28. doi: 10.1016/j.vaccine.2016.10.084. Epub 2016 Dec 22.
The vast majority of vaccines used throughout the world are supplied by the private sector. It is essential therefore that the industry is closely engaged in future policy developments at a national and international level and is able to respond to the changing needs and priorities that may be required to ensure the success of Mission Grand Convergence. Uniquely, the major vaccine companies have the expertise and technical capacity to develop, produce and supply vaccines on a global scale. Through partnering with Governments, charities and NGOs, they must play a pivotal role in the Mission and, at the same time as agreeing on objectives that may not be entirely market driven, must be able to sustain their commercial obligations to shareholders. Similarly, small and medium sized companies, with the global investor market and government incentives that underpin and support them, also have a very important role to play; for example in innovation around a given disease and on technology, process and platform development across the whole value chain. The industry at large is therefore an essential player. Indeed Mission Grand Convergence can only succeed with the full and willing participation of the vaccines industry.
全球使用的绝大多数疫苗由私营部门供应。因此，至关重要的是，该行业要密切参与国家和国际层面的未来政策制定，并能够应对不断变化的需求和优先事项，这些需求和优先事项可能是确保“大融合使命”取得成功所必需的。主要疫苗公司具有独特的专业知识和技术能力，能够在全球范围内研发、生产和供应疫苗。通过与政府、慈善机构和非政府组织合作，它们必须在该使命中发挥关键作用，并且在商定可能并非完全由市场驱动的目标的同时，必须能够履行对股东的商业义务。同样，中小型公司在全球投资者市场以及支持它们的政府激励措施的支撑下，也能发挥非常重要的作用；例如在围绕特定疾病的创新以及整个价值链的技术、流程和平台开发方面。因此，整个行业都是至关重要的参与者。事实上，只有疫苗行业充分且自愿地参与，“大融合使命”才能取得成功。
